Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1195 - Overall survival of elderly glioblastoma patient treated with concurrent chemoradiotherapy: A retrospective review with comparison to non-elderly counterpart


24 Nov 2018


Poster display - Cocktail


Cancer in Older Adults;  Radiation Oncology

Tumour Site

Central Nervous System Malignancies


Arunangshu Das


Annals of Oncology (2018) 29 (suppl_9): ix21-ix22. 10.1093/annonc/mdy429


A. Das

Author affiliations

  • Radiotherapy And Oncology, Square Hospital Ltd, 1205 - Dhaka/BD


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1195


Age is considered to be one of the most important prognostic factor for Glioblastoma (GBM) patients. Elderly patients, age more than 65 years make up a large percentage who are newly diagnosed with GBM. Elderly patients face considerable challenges in tolerating standard therapy and sometime experience significantly shorter survival and poor quality of life compared with non-elderly patients.


Retrospective analysis was done of 72 GBM patients treated with concurrent Temozolamide (TMZ) with 60 Gray of Radiotherapy in 30 fractions followed by 6 cycles of adjuvant TMZ, treated at Square Hospitals Ltd from 2014 to 2017. Overall survival, progression free survival and quality of life were estimated and compared between elderly and non-elderly group.


A total of 72 patients were analyzed, 37 in elderly group and 35 in non-elderly group. The median age was 70 years. Median pre-radiation Karnofsky performance scale (KPS) was 60 (range: 40 - 90). The median overall survival (OS) was 6.8 months and median progression-free survival (PFS) was 4.2 months in elderly patients. However, in non-elderly patients OS was 14 months and PFS was 6 months. Quality of life was poor in elderly GBM patients.


Overall survival and progression free survival were shorter for elderly patients with GBM than for non-elderly patients. Elderly GBM patients need to be considered for less intensive therapy like hypofractionated radiotherapy with or without TMZ. Further prospective randomized studies are needed to find out the appropriate treatment strategy for elderly patient with GBM.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Square Hospitals Ltd.


Has not received any funding.


The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.